CRTC2 (CREB-regulated transcription coactivator 2), also known as TORC2. is a transcriptional coactivator that plays a pivotal role in regulating energy homeostasis and glucose metabolism. It functions by binding to CREB (cAMP response element-binding protein), enhancing its ability to activate target genes involved in gluconeogenesis, lipid metabolism, and stress responses. CRTC2 activity is tightly regulated by phosphorylation-dependent nucleocytoplasmic shuttling. Under fasting conditions, dephosphorylated CRTC2 translocates to the nucleus, where it interacts with CREB to upregulate gluconeogenic genes like *PGC-1α* and *G6Pase*. Insulin signaling, via Akt-mediated phosphorylation, promotes CRTC2 sequestration in the cytoplasm, thereby suppressing hepatic glucose production.
CRTC2 antibodies are essential tools for studying its expression, localization, and post-translational modifications. These antibodies are typically generated against specific epitopes, such as the N-terminal or C-terminal regions, and validated for applications like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). Researchers use CRTC2 antibodies to investigate its role in metabolic disorders, particularly type 2 diabetes and obesity, where dysregulated CRTC2-CREB signaling contributes to hyperglycemia. Studies also explore CRTC2's interaction with pathways like AMPK and mTOR, linking cellular energy status to transcriptional control. Reliable CRTC2 antibodies help elucidate mechanisms underlying metabolic syndrome and potential therapeutic targets.